Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis
- PMID: 36927370
- DOI: 10.1080/14656566.2023.2192867
Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis
Comment in
-
Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis.Expert Opin Pharmacother. 2023 May;24(7):873. doi: 10.1080/14656566.2023.2203813. Epub 2023 Apr 19. Expert Opin Pharmacother. 2023. PMID: 37057628 No abstract available.
Comment on
-
What are the pharmacotherapeutic considerations for the treatment of myasthenia gravis?Expert Opin Pharmacother. 2022 Sep;23(13):1471-1474. doi: 10.1080/14656566.2022.2122710. Epub 2022 Sep 14. Expert Opin Pharmacother. 2022. PMID: 36104973 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical